TD Asset Management
ENTA icon

TD Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

TD Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,700
Closed -$433K – 1427
2023
Q1 		$433K Hold
10,700
– – ﹤0.01% 1290
2022
Q4 		$498K Hold
10,700
– – ﹤0.01% 1285
2022
Q3 		$561K Buy
10,700
+500
+5% +$29.2K ﹤0.01% 1276
2022
Q2 		$482K Sell
10,200
-3,100
-23% -$168K ﹤0.01% 1298
2022
Q1 		$947K Sell
13,300
-12,200
-48% -$794K ﹤0.01% 1244
2021
Q4 		$1.91M Buy
25,500
+6,500
+34% +$510K ﹤0.01% 1144
2021
Q3 		$1.08M Buy
+19,000
New +$939K ﹤0.01% 1232
2021
Q2 		– Sell
-17,847
Closed -$880K – 1535
2021
Q1 		$880K Sell
17,847
-5,300
-23% -$264K ﹤0.01% 1285
2020
Q4 		$974K Hold
23,147
– – ﹤0.01% 1192
2020
Q3 		$1.06M Sell
23,147
-6,100
-21% -$296K ﹤0.01% 1074
2020
Q2 		$1.47M Buy
29,247
+800
+3% +$41.4K ﹤0.01% 951
2020
Q1 		$1.46M Sell
28,447
-4,600
-14% -$245K ﹤0.01% 901
2019
Q4 		$2.04M Sell
33,047
-3,300
-9% -$205K ﹤0.01% 922
2019
Q3 		$2.18M Sell
36,347
-2,201
-6% -$163K ﹤0.01% 892
2019
Q2 		$3.25M Buy
38,548
+3,400
+10% +$306K ﹤0.01% 798
2019
Q1 		$3.36M Buy
35,148
+3,331
+10% +$299K 0.01% 789
2018
Q4 		$2.25M Buy
31,817
+145
+0.5% +$11.1K ﹤0.01% 887
2018
Q3 		$2.71M Sell
31,672
-9,089
-22% -$910K ﹤0.01% 920
2018
Q2 		$4.72M Buy
40,761
+27,319
+203% +$2.73M 0.01% 719
2018
Q1 		$1.09M Buy
13,442
+308
+2% +$23.7K ﹤0.01% 1041
2017
Q4 		$771K Buy
+13,134
New +$658K ﹤0.01% 1108

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TD Asset Management's ENTA Position: Q2 2023 in Review

TD Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2023, closing a stake of 10,700 shares — an estimated $433K sold.

TD Asset Management first reported a position in ENTA in Q4 2017 and held it in 21 quarters. The position peaked at $4.72M in Q2 2018. 133 funds tracked by Wall St. Rank hold ENTA as of Q2 2023.

  • TD Asset Management reported no remaining Enanta Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TD Asset Management sold 10,700 Enanta Pharmaceuticals shares in Q2 2023, an estimated $433K.
  • TD Asset Management first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 21 quarters.
  • TD Asset Management's Enanta Pharmaceuticals position peaked at $4.72M in Q2 2018.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2023.

Based on TD Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.